Replies to post #6046 on IonQ Inc (IONQ)

[Konaploinks]

Here’s a clear comparison of insider activity for IonQ’s key executives, showing how Peter Chapman stacks up:

?

📊 Insider Sales by IonQ Executives (Last 6 Months)
Executive
Role
Shares Sold
Value (~USD)
Remaining Shares
Notes
Peter Hume Chapman
Executive Chair (former CEO)
˜?2.04?M
˜?$38?M
~402?K–414?K
Sold large tranches mainly March ’25; small tax-cover sale (~12K)
Niccolo?de?Masi
President & CEO
9,280
˜?$392?K
~712?K
~1.3% stake sale June ’25
Rima?Alameddine
Chief Revenue Officer
~20?K+1.4?K
˜?$372?K+$30?K ˜?$402?K
~572?K
Multiple smaller sales in March
Thomas?G.?Kramer
CFO
~18.5?K
˜?$353?K
~944?K
2-3 small sales in March
William?F.?Scannell
Non-Exec Director
—
? +93?K buy, ~$2?M
~135?K
Only insider net buying recently


?

🧭 Key Takeaways
   •   Chapman: Dominates insider activity—sold ~82–83% of his post-exercise holdings (~2?M shares for ~$37?M) mainly in March, plus a small tax-cover sale (~12?K shares). Still retains ~400?K shares worth ~$16?M, signaling both cash realization and remaining commitment. ?
   •   de?Masi: Moderately sold in June (~9,280 shares, ~1.3% of his holdings), bringing his remaining stake to 712?K shares ($28?M). A much smaller exit relative to Chapman. ?
   •   Alameddine & Kramer: Executed modest insider sales (~20?K and ~18?K shares respectively) in March, likely part of routine vesting or tax liquidity. Both keep substantial holdings. ?
   •   Scannell: The only insider who purchased recently (+93?K shares, ~$2?M), boosting his stake by ~41%. ?

?

💡 Interpretation
   •   Strategic vs routine selling: Chapman’s sales were large and likely profit-realizing (including post-exercise conversion), while others’ sales appear modest, possibly vesting/tax actions.
   •   Leadership confidence: Despite selling much, Chapman retains a meaningful stake (~400?K shares). de Masi, Alameddine and Kramer continue to hold sizable positions.
   •   Net insider buying: Scannell’s purchase stands out—suggesting board-level confidence.

?

✅ Summary
   •   Chapman has materially monetized his equity but keeps strong “skin in the game.”
   •   de?Masi sold a small percentage, retaining a larger relative position.
   •   CRO & CFO holdings largely untouched beyond routine liquidity.
   •   Directors show confidence: Scannell’s buy is a bullish signal, others are flat.

Let me know if you’d like a deeper dive into vesting structures, insider trends over time, or comparisons with similar firms!